Prevention of intrahepatic hepatocarcinoma recurrence in patients with viral cirrhosis: Two potential options

Minerva Gastroenterologica e Dietologica

Volumn 52, Issue 1, 2006, Pages 47-52

  Tabone, M ^a,b   Pellicano, R ^c  

^a MAURIZIANO HOSPITAL   (Italy)

^b Institute for Cure and Cancer Research   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

Hepatocellular neoplasms; Liver; Liver cirrhosis

Indexed keywords

ALPHA INTERFERON; IODINATED POPPYSEED OIL;

CLINICAL TRIAL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; RECURRENT CANCER; REVIEW; SURVIVAL RATE; TUMOR VOLUME;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 33646343203     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
2. Stroffolini T. Etiological factor of hepatocellular carcinoma in Italy. Minerva Gastroenterol Dietol 2005;51:1-5.
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127 Suppl 1:S35-S50.
4. Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996;83:1219-22.
5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
6. Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L et al. Liver transplantation for small hepatocellular carcinoma: the TNM classification does not have prognostic power. Hepatology 1998;27:1572-7.
7. Michel J, Suc B, Fourtanier G, Durand D, Rumeau JL, Rostaing L et al. Recurrence of hepatocellular carcinoma in cirrhotic patients after liver resection or transplantation. Transplant Proc 1995;27:1798-800.
8. Mazziotti A, Grazi GL, Cavallari A. Surgical treatment of hepatocellular carcinoma on cirrhosis: a western experience. Hepatogastroenterology 1998;45 Suppl 3:1281-7.
9. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655-61.
10. Lin S-M, Lin C-J, Lin C-C, Hsu C-W, Chen Y-C. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151-6.
11. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122-30.
12. Shimada M, Takenata K, Gion T, Fujiwara Y, Kajiyama K, Maeda T et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996;111:720-6.
13. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232:10-24.
14. Mion F, Grozel L, Boillot O, Paliard P, Berger F. Adult cirrhotic liver explants: precancerous lesions and undetected small hepatocellular carcinomas. Gastroenterology 1996;11:1587-92.
15. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-7.
16. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma prevention study group. N Engl J Med 1996;334:1561-7.
17. Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004;292:385-91.
18. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
19. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001;33:346-56.
20. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q et al. High-dose and long-term therapy with interferon alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000;32:43-8.
21. Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N, Takemoto Y et al. Interferon- alphaCon1 suppresses proliferation of liver cell lines in vitro and in vivo. J Hepatol 2004;41:782-9.
22. Locker GJ, Mader RM, Steiner B, Wenzl E, Zielinski CC, Steger GG. Benefit of interferon-alpha2b in a patient with unresectable hepatoma and chronic infection with hepatitis C virus. Eur J Gastroenterol Hepatol 2000;12:251-3.
23. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:1-5.
24. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C and persistent viremia. Gastroenterology 1999;117:1364-72.
25. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
26. Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593-602.
27. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor. A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-32.
28. Suou T, Mitsuda A, Koda M, Matsuda H, Maruyama S, Tanaka H et al. Interferon-alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001;20:301-11.
29. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med 2001;134:963-7.
30. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T et al. Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res 2001;91:59-66.
31. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306.
32. Craxì A, Cammà C. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005;9:329-46.
33. Mazzaferro V, Romito R, Colombo M, Capussotti L, Polastri R, Pellicci R et al. Prospective randomised trial on IFN-therapy for the secondary prevention of HCC recurrence after curative resection in HCV related cirrhosis. Preliminary report. J Hepatol 2004;40 Suppl 1: A94 .
34. Tabone M, Laudi C, Vernetto A, Daperno M, Galatola G, Pera A. Peg-IFN plus ribavirin treatment in the prevention of HCC recurrence. Dig Liver Dis 2005;37 Suppl 1:A59.
35. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156-61.
36. Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J et al. Adjuvant intra-arterial iodine 131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797-801.
37. Partensky C, Sassolas G, Henry L, Paliard P, Maddern GJ. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. Arch Surg 2000;135:1298-300.
38. Boucher E, Corbinais S, Rolland Y, Bourget P, Guyader D, Boudjema K et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003;38:1237-41.
39. Tabone M, Viganö L, Laudi C, Ferrero A, Pellerito R, Capussotti L. Adijuvant iodine-131-labelled lipiodol for prevention of intrahepatic recurrence of hepatocellular carcinoma: wich is the best treatment schedule? Hepatology 2005;41:1433.